🇺🇸 FDA

Intelligence Platform

Patents

Browse 92 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12390512

Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumon

SHANGHAI REINOVAX BIOLOGICS CO., LTD · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384854

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Takeda Pharmaceutical Company Limited · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12344585

Crystalline salts of a plasma kallikrein inhibitor

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338439

Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and k

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12329805

Dosage forms of tissue kallikrein 1

DiaMedica Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240918

Bispecific antibodies against plasma kallikrein and factor XII

Takeda Pharmaceutical Company Limited · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221441

Plasma kallikrein inhibitors and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162838

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116346

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12110343

Anti-plasma kallikrein antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065448

Heteroaryl plasma kallikrein inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11905285

Inhibitors of plasma kallikrein and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857608

Dosage forms of tissue kallikrein 1

DiaMedica Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840686

Modulation of prekallikrein (PKK) expression

Ionis Pharmaceuticals, Inc. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11807605

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787796

Plasma Kallikrein inhibitors and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708333

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708332

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685721

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618733

Crystalline salts of a plasma kallikrein inhibitor

BioCryst Pharmaceuticals, Inc. · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618731

Prodrugs of kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11584735

Solid forms of a plasma kallikrein inhibitor and salts thereof

KalVista Pharmaceuticals Limited · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505620

Methods of detecting plasma kallikrein

Takeda Pharmaceutical Company Limited · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479769

Technique for treating cancer using structurally-reinforced S-TuD

GeneDesign, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted